# AI in Chemotherapy & Oncology

## Overview

AI is transforming cancer treatment through precision oncology — matching the right treatment to the right patient at the right time. From predicting drug response to optimizing dosing regimens and identifying new therapeutic targets, AI is accelerating every phase of the cancer care continuum.

**Market Size:** Precision oncology AI — $3.8B (2024) → projected $14.5B by 2030

---

## Key Applications

### 1. Treatment Selection & Precision Oncology

| Application | Description | Key Players | Impact |
|------------|-------------|-------------|--------|
| Genomic-guided therapy | Match mutations to targeted therapies | Tempus, Foundation Medicine, Guardant | 30-40% patients get matched therapy |
| Tumor molecular profiling | Comprehensive genomic profiling (CGP) | Foundation Medicine (FoundationOne CDx) | FDA-approved companion diagnostic |
| Treatment response prediction | Predict chemo/immunotherapy response | Tempus, SOPHiA Genetics | 15-25% improvement in response rates |
| Liquid biopsy AI | Blood-based cancer detection/monitoring | Guardant Health, GRAIL, Natera | Non-invasive monitoring |
| Biomarker discovery | AI-identified new biomarkers | Recursion, Owkin | Accelerated biomarker validation |

### 2. Chemotherapy Dose Optimization

| Application | Description | Key Players | Status |
|------------|-------------|-------------|--------|
| Pharmacokinetic modeling | Predict drug levels in individual patients | InsightRX, DoseMeRx | FDA-cleared |
| Toxicity prediction | Predict severe adverse events before they occur | Various research groups | Clinical trials |
| Dose adjustment algorithms | AI-optimized dosing based on patient factors | InsightRX, TDMx | Clinical use |
| Combination therapy optimization | Optimal drug combinations | Insilico Medicine, BenevolentAI | Research/Clinical |
| Treatment scheduling | Optimal infusion timing and frequency | Research stage | Clinical trials |

### 3. Radiation Therapy AI

| Application | Description | Key Players | Status |
|------------|-------------|-------------|--------|
| Auto-contouring | AI segmentation of organs/tumors for planning | Limbus AI, MVision, Therapanacea | FDA-cleared |
| Treatment planning | AI-optimized radiation dose distribution | RaySearch, Varian (Siemens) | Clinical use |
| Adaptive radiotherapy | Real-time plan adjustment during treatment | Varian Ethos, Elekta Unity | FDA-cleared |
| Proton therapy planning | AI-optimized proton beam therapy | IBA, Varian | Emerging |
| Quality assurance | AI-based plan verification | Radformation, Sun Nuclear | Clinical use |

### 4. Immunotherapy AI

| Application | Description | Key Players | Status |
|------------|-------------|-------------|--------|
| PD-L1/TMB prediction | Predict immunotherapy response from pathology | PathAI, Owkin | Research/Clinical |
| Neoantigen prediction | Identify targets for cancer vaccines | Gritstone Bio, BioNTech | Clinical trials |
| CAR-T optimization | AI-designed chimeric antigen receptors | Absci, Generate Biomedicines | Research |
| Immune profiling | Tumor microenvironment analysis | Akoya Biosciences, Ultivue | Clinical use |
| Combination prediction | Predict immunotherapy + chemo synergy | Tempus, Predicine | Clinical trials |

### 5. Cancer Screening & Early Detection

| Application | Description | Key Players | Status |
|------------|-------------|-------------|--------|
| Multi-cancer early detection | Blood tests detecting 50+ cancers | GRAIL (Galleri), Exact Sciences | Clinical/FDA review |
| Circulating tumor DNA (ctDNA) | Monitor minimal residual disease | Natera (Signatera), Guardant | FDA-cleared (some) |
| Lung cancer screening AI | Low-dose CT analysis | Optellum, Riverain | FDA-cleared |
| Colorectal cancer screening | AI-enhanced colonoscopy | GI Genius (Medtronic), Iterative Scopes | FDA-cleared |
| Cervical cancer screening | AI-powered Pap smear analysis | Hologic (Genius Digital), BD | FDA-cleared |

---

## Precision Oncology Platforms

### Comprehensive Platforms
| Platform | Company | What It Does | Patients Served |
|----------|---------|-------------|----------------|
| Tempus ONE | Tempus | Genomic sequencing + AI treatment matching | 500K+ patients |
| FoundationOne CDx | Foundation Medicine (Roche) | CGP for 300+ genes | 1M+ tests |
| Guardant360 | Guardant Health | Liquid biopsy CGP | 400K+ tests |
| Caris Molecular Intelligence | Caris Life Sciences | Multi-omic profiling | 300K+ patients |
| SOPHiA DDM | SOPHiA Genetics | Genomic data analysis | 1M+ analyses |
| Oncotype DX | Exact Sciences | Breast cancer recurrence score | 1.5M+ tests |
| MammaPrint | Agendia | 70-gene breast cancer assay | 200K+ tests |

### Molecular Tumor Boards
AI-assisted tumor boards analyze complex genomic data to recommend treatments:
- **Watson for Oncology (IBM)** — Discontinued but pioneered the concept
- **Tempus AI** — Real-time genomic analysis during tumor boards
- **OncoKB** — Memorial Sloan Kettering's precision oncology knowledge base
- **CIViC** — Community-curated clinical interpretation of variants in cancer

---

## AI in Specific Cancer Types

### Breast Cancer
| Application | AI Tool | Evidence Level |
|------------|---------|---------------|
| Mammography screening | Lunit INSIGHT MMG, iCAD | High (RCTs) |
| Pathology grading | Paige Breast, PathAI | FDA-cleared |
| Recurrence prediction | Oncotype DX + AI | Standard of care |
| Treatment planning | Tempus, FoundationOne | Clinical use |
| Surgery planning | AI-guided lumpectomy margins | Research |

### Lung Cancer
| Application | AI Tool | Evidence Level |
|------------|---------|---------------|
| Screening (LDCT) | Optellum, Riverain | FDA-cleared |
| Biopsy guidance | Ion (Intuitive), Monarch (J&J) | FDA-cleared |
| PD-L1 prediction | Owkin, Lunit | Research |
| Treatment response | Tempus, Foundation Medicine | Clinical use |

### Prostate Cancer
| Application | AI Tool | Evidence Level |
|------------|---------|---------------|
| MRI analysis | Avenda Health, ProGrade | FDA-cleared |
| Gleason grading | Paige Prostate, Ibex | FDA-cleared |
| Active surveillance | Artera AI | FDA-cleared |
| Surgery planning | Avenda Health | Clinical trials |

### Colorectal Cancer
| Application | AI Tool | Evidence Level |
|------------|---------|---------------|
| Polyp detection | GI Genius (Medtronic) | FDA-cleared |
| MSI prediction | PathAI, Owkin | Research |
| ctDNA monitoring | Natera Signatera | FDA-cleared |

---

## Research Papers (Must-Read)

### Foundational
1. **"Deep learning enables pathologist-level cancer diagnosis"** — Multiple studies establishing AI pathology
2. **"Multi-cancer early detection with cell-free DNA"** — GRAIL/Galleri validation studies
3. **"AI-guided precision oncology clinical decision support"** — Tempus publications
4. **"Predicting chemotherapy response with deep learning"** — Various groups (Nature Medicine)
5. **"Comprehensive genomic profiling in oncology"** — Foundation Medicine landmark studies

### Recent (2024-2025)
1. **"Foundation models for cancer pathology"** — CONCH, UNI models
2. **"AI-predicted neoantigen vaccines"** — BioNTech/Gritstone results
3. **"Liquid biopsy AI for minimal residual disease"** — Natera/Guardant updates
4. **"Large language models for oncology decision support"** — Multiple groups
5. **"Federated learning for multi-center oncology AI"** — NVIDIA FLARE applications

---

## Clinical Decision Support Tools

### Currently Available
| Tool | Function | Access |
|------|----------|--------|
| OncoKB | Variant interpretation for precision oncology | Free (academic) |
| CIViC | Community variant interpretation | Open source |
| My Cancer Genome | Genotype-to-treatment database | Free |
| Clinical Trials.gov + AI | AI-matched clinical trial finder | Free |
| Tempus Lens | AI-powered literature search for oncologists | Subscription |

### AI Clinical Trial Matching
- **Tempus Trial Hub** — AI matches patients to trials based on genomic profile
- **Flatiron (Roche)** — Real-world evidence + trial matching
- **TrialJectory** — Patient-facing trial matching
- **Deep 6 AI** — Clinical trial patient recruitment

---

## Challenges

1. **Tumor heterogeneity** — Cancers evolve and vary within a single patient
2. **Data silos** — Cancer data fragmented across hospitals
3. **Cost** — Comprehensive genomic profiling costs $3,000-5,000+
4. **Interpretation** — Variants of unknown significance (VUS) remain common
5. **Access equity** — Precision oncology primarily available in developed countries
6. **Resistance prediction** — Hard to predict when cancer will resist treatment
7. **Combination complexity** — Exponential drug combination possibilities
8. **Regulatory lag** — Companion diagnostic approvals take years

---

## Future Directions

1. **Digital twins for cancer** — Virtual patient models to simulate treatment response
2. **AI-designed cancer drugs** — De novo drug design for specific mutations
3. **Real-time adaptive therapy** — Adjust treatment based on continuous monitoring
4. **Organoid-guided AI** — Patient tumor organoids + AI for drug testing
5. **Pan-cancer foundation models** — Universal cancer AI models
6. **Closed-loop chemotherapy** — AI-controlled infusion pumps with real-time monitoring
7. **Cancer vaccines at scale** — AI-designed personalized mRNA cancer vaccines
8. **Spatial biology AI** — Single-cell spatial analysis of tumor microenvironment

---

*Sources: ASCO, ESMO, Nature Medicine, Nature Reviews Cancer, FDA, NCI*
*Updated: February 2025*
